



Personal information

First name(s) / Surname(s) **Leonardo Michele Fabbri**
H Index October 2019: 113 Google Scholar; 95 Scopus

Address **Viale Verdi, 59 - 41121, Modena, Italy**

Telephone **+39 059-235802; +39 0532291297**

Fax **+39 059 235802; +39 0532 291297**

Mobile **+39 348-9902706; +39 348-9934593**

E-mail **leonardo.fabbri20@gmail.com**

Nationality **Italian**

Date of birth **June 8, 1947**

Gender **Male**

Occupational field **Medical Doctor**

Work experience

University of Ferrara
 From 1 October 2017 to date
 Eminent Scholar of Internal and Respiratory Medicine

University of Gothenburg
 From 1 May 2017 to date
 Visiting Professor of Internal and Respiratory Medicine

Name and address of employer **University of Modena and Reggio Emilia – Modena Hospital (-2016)**
Via Università 5 - 41121 Modena – Italy

From 1 November 2015 to 31 October 2016
Professor of Internal Medicine
Director of Internal Medicine
Director of the Department of Internal Medicine

Academic positions held **From 1 March 2000 to 31 October 2015**
Professor of Respiratory Diseases (2000-)
Director of Respiratory Diseases (2000-)
Director of Medical Oncology (2013-2015)
Director of the Department of Oncology, Hematology and Respiratory Diseases (2010-2015)
Professor and Director of Internal Medicine (2016)

Teaching positions held **From 2003 to 2007 and from 2008 to 2010**
Director of the Post-Graduate School of Respiratory Diseases
University – Hospital of Modena e Reggio Emilia

From 2003 to 2007
 Director, School of Physiotherapy
 University – Hospital of Modena e Reggio Emilia

From 1992 to 2000
 Associate Professor of Respiratory Diseases
 Director of the Research Centre for Asthma and COPD (1993-2000)
 University of Ferrara
 Via Savonarola, 9 - 44121 FERRARA – Italy

From 1991 to 1992
 Assistant Professor of Medicine (Riceratore), Respiratory Diseases
 University – Hospital of Ferrara

From 1981 to 1991
 Assistant Professor of Medicine (Riceratore), Occupational Medicine
 Director of the Laboratory of Respiratory Physiology (1983-1991)
 University – Hospital of Padova
 Via 8 Febbraio 1848 – 35100 Padova - Italy

Education and training

Dates	1961-1966
Title of qualification awarded	High School I. Nievo-Padova Scientific Maturity
	1966-1972
	Degree in Medicine and Surgery, 110/110 summa cum laude, University of Padova - Italy
Post-Graduate Training	Board in Occupational Medicine, 1975, University of Padua, 70/70 summa cum laude Board in Respiratory Diseases, 1978, University of Bologna, 70/70 summa cum laude
	1980 – 1981 Visiting Scientist Department of Respiratory Diseases Tulane University, New Orleans, USA, School of Medicine
	1981 – 1983 Visiting Scientist University of California, San Francisco, Cardiovascular Research Institute

Personal skills and competences

Mother tongue(s) **Italian**

Other language(s) **English**

Self-assessment

European level (*)

Language

Understanding		Speaking		Writing
Listening	Reading	Spoken interaction	Spoken production	
excellent	excellent	excellent	excellent	excellent

(*) [Common European Framework of Reference for Languages](http://europass.cedefop.europa.eu)

Editorial assignments

Associate Editor for :

- American Journal Respiratory and Critical Care Medicine, 1999-2009
- American Journal Respiratory and Critical Care Medicine, 2015 – to date
- European Respiratory Journal, 2004 -2018
- Lancet Respiratory Medicine, 2013 - to date
- Canadian Respiratory Journal, 2016-2019
- Journal of COPD, 2004 - to date
- Respiratory Research, 2005 - to date
- European Journal of Clinical Investigation 2010 - 2019
- Italian Journal of Internal Medicine, 2010 - to date
- PLOS-ONE, september 2013 – 2019

Reviewer of Research Projects

For:

European Union almost yearly from 2005
 Framework Program 7
 Innovative Medicine Initiative
 German Center for Lung Research, 2011
 Spanish Clinical Research Network- Instituto de Salud Carlos III - Ministerio de Ciencia
 The Swedish Foundation for Strategic Research
 Slovenian Research Agency
 Research Council K.U.Leuven, Belgium
 Cineca – referee scientific products (VQR) for the Italian Ministry of University
 Cineca – referee research projects (FIRB) for the Italian Ministry of University
 French Ministry of Research, 2015

Role in Scientific Societies

Presidential cycle - European Respiratory Society (ERS) 2005-2009
 President - European Respiratory Society (ERS) 2007-2008
 Member of the International Committee for the "Global Initiative on Asthma", sponsored by the NHLBI and the WHO, 1990-1997
 Member of the International Committee Committee, International Committee for the "Global Strategy on COPD", sponsored by the NHLBI and the WHO, 1997-2017

Honors

Honorary Lecturer, Michael Newhouse Lectureship, "Occupational Asthma, 21 February 1994 aster University, Hamilton, Ontario, Canada
 Honorary Member, Austrian Society of Hospital Pulmonology, 1998
 Elected Member, Fleischner Society, 1998-
 Honorary member of the *Collegii Regalis Modicorum Londinenses*, (Royal College of Physicians) April 2000-
 Honorary Lecturer "Jeff Drazen's Lecture", Harvard School of Public Health – Massachusetts General Hospital, Boston 10-11 October 2002
 Honorary Member of the Italia Association of Hospital Internists (FADOI)
 Honorary Citizen of Santa Sofia (FC), City of origin of his Family
 Giant in Respiratory Medicine, American College of Chest Physicians, 2016
 Margareth Turner Warwick Honorary Lecturer, Imperial College, London, 2017
 Eminent Scholar, University of Ferrara, Italy, 2016

Principal or co-principal Investigator of competitive research Grants

Italian Ministry of University and Research, continuously from 1980/1995
 European Community, 2 Grants on Severe Asthma
 Italian Ministry of Health, 5 Grants of 1) € 700,000, 2005, Principal Investigator, Role of pro-calcitonin in prescribing antibiotics for AECOPD, 2) € 750,000, 2010, Principal Investigator, Assessment of severity of patients with multimorbidity 3) € 1,000,000, 2006, co-principal investigator, for the Comparison between guideline recommended treatment of mild asthma with regular BDP + prn albuterol versus placebo and prn ICS + albuterol; 4) € 1,000,000, 2011, co-principal investigator, for the Comparison between guideline recommended treatment of moderate asthma with regular budesonide/formoterol + prn albuterol versus regular placebo + prn budesonide/formoterol; 5) € 3,000,000, 2007, Co-principal Investigator for the assessment of inhaled ICS containing combinations versus non-ICS combinations in the 1 year follow-up treatment of COPD patients discharged after an AECOPD

PUBLICATIONS (> 550) To see the work, go to the website of the National Library of Medicine
<http://www.ncbi.nlm.nih.gov/pubmed> typing into the "Search for": Fabbri L an Fabbri LM)

Leonardo M. Fabbri, MD, FERS

Ten most relevant original publications

Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M; ATLANTIS study group. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. *Lancet Respir Med*. 2019 Mar 12. pii: S2213-2600(19)30049-9. doi: 10.1016/S2213-2600(19)30049-9. [Epub ahead of print] PubMed PMID: 30876830.

Ferguson GT, Rabe KF, Martinez FJ, Fabbri LM, Wang C, Ichinose M, Bourne E, Ballal S, Darken P, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. *Lancet Respir Med*. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16. Erratum in: *Lancet Respir Med*. 2018 Oct 4;:. PubMed PMID: 30232048.

Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, Scuri M, Roche N, Singh D. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. *Lancet*. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9. Erratum in: *Lancet*. 2018 Feb 26;:. PubMed PMID: 29429593.

Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicenter randomised controlled trial. *Lancet*. 2015 Mar 7;385(9971):857-66. doi: 10.1016/S0140-6736(14)62410-7. Epub 2015 Feb 13. PubMed PMID: 25684586.

Papi A, Marku B, Scichilone N, Maestrelli P, Paggiaro P, Saetta M, Nava S, Folletti I, Bertorelli G, Bertacco S, Contoli M, Plebani M, Barbaro MPF, Spanevello A, Aliani M, Pannacci M, Morelli P, Beghé B, Fabbri LM; AIFASMA Study Group. Regular versus as-needed budesonide and formoterol combination treatment for moderate asthma: a non-inferiority, randomised, double-blind clinical trial. *Lancet Respir Med*. 2015 Feb;3(2):109-119. doi: 10.1016/S2213-2600(14)70266-8. Epub 2014 Dec 4. PubMed PMID: 25481378.

Papi A, Corradi M, Pigeon-Francisco C, Baronio R, Siergiejko Z, Petruzzelli S, Fabbri LM, Rabe KF. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. *Lancet Respir Med*. 2013 Mar;1(1):23-31. doi: 10.1016/S2213-2600(13)70012-2. Epub 2013 Mar 4. PubMed PMID: 24321801.

Vogelmeier C, Hederer B, Glaab T, Schmidt H, Rutten-van Mölken MP, Beeh KM, Rabe KF, Fabbri LM; POET-COPD Investigators. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. *N Engl J Med*. 2011 Mar 24;364(12):1093-1103. doi: 10.1056/NEJMoa1008378. PubMed PMID: 21428765.

Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF; M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):695-703. doi: 10.1016/S0140-6736(09)61252-6. PubMed PMID: 19716961.

Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ; M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. *Lancet*. 2009 Aug 29;374(9691):685-94. doi: 10.1016/S0140-6736(09)61255-1. Erratum in: *Lancet*. 2010 Oct 2;376(9747):1146. PubMed PMID: 19716960.

Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G, Fabbri LM; BEST Study Group. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. *N Engl J Med*. 2007 May 17;356(20):2040-52. PubMed PMID: 17507703.

Ten most relevant editorial/reviews

Fabbri LM, Beghe B, and Papi A. Blood eosinophils for the management of COPD patients? *Lancet Respir Med*. 2018, on line 17 October 2018

Fabbri LM, Roversi S, Beghé B. Triple therapy for symptomatic patients with COPD. *Lancet*. 2017 May 13;389(10082):1864-1865. doi: 10.1016/S0140-6736(17)30567-6. Epub 2017 Apr 4. PubMed PMID: 28385354.

Papi A, Fabbri LM. Management of patients with early mild asthma and infrequent symptoms. *Lancet*. 2017 Jan 14;389(10065):129-130. doi: 10.1016/S0140-6736(16)32111-0. Epub 2016 Nov 30. PubMed PMID: 27912984.

Fabbri LM. Symptoms in Smokers with Preserved Pulmonary Function. *N Engl J Med*. 2016 Sep 1;375(9):897. doi: 10.1056/NEJMc1608235. PubMed PMID: 27579643.

Fabbri LM. Smoking, Not COPD, as the Disease. *N Engl J Med*. 2016 May 12;374(19):1885-6. doi: 10.1056/NEJMe1515508. PubMed PMID: 27168438.

Roversi S, Fabbri LM, Sin DD, Hawkins NM, Agustí A. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. *Am J Respir Crit Care Med*. 2016 Dec 1;194(11):1319-1336. Review. PubMed PMID: 27589227

Fabbri LM. Benralizumab: for asthma, not yet for COPD. *Lancet Respir Med*. 2014 Nov;2(11):862-863. doi: 10.1016/S2213-2600(14)70225-5. Epub 2014 Oct 8. PubMed PMID: 25306558.

Fabbri LM, Beghé B, Yasothan U, Kirkpatrick P. Roflumilast. *Nat Rev Drug Discov*. 2010 Oct;9(10):761-2. doi: 10.1038/nrd3276. PubMed PMID: 20885403.

Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome? *Lancet*. 2007 Sep 1;370(9589):797-9. PubMed PMID: 17765529.

Fabbri LM. Does mild persistent asthma require regular treatment? *N Engl J Med*. 2005 Apr 14;352(15):1589-91. PubMed PMID: 15829540.

BOOKS FOR MEDICAL STUDENTS

Rugarli C. *Medicina Interna Sistemica*. VII, VIII e IX Edizione. Parte 1: Malattie dell' Apparatto Respiratorio, A cura di LM Fabbri LM. EDRA-Masson, Milano, 2010 (VI Ed), 2015 (VII Edi), 2020 (VIII Edition, in preparation)

Fabbri LM e Marsico SA. *Trattato di Malattie Respiratorie*. Edises, Napoli, 2013

